Skip to main content

Miraculins Raises $505K in Private Placement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Miraculins has completed a private placement of 10.2 million units, raising C$510,000 (US$505,000) in proceeds.

The Winnipeg, Canada-based diagnostics firm said that it has sold the units at C$.05 each. The units are comprised of one common share and one share purchase warrant. Each warrant entitles the holder to purchase one share at a price of C$.10 for a period of 12 months after the warrant is issued.

Miraculins noted that the warrants are callable, at its option, in the event the shares trade at or above $.14 per share for any 20 out of 30 consecutive trading days.

Miraculins, which makes biomarker-based diagnostic tests, said that it will use the proceeds for R&D and working capital purposes.

Its shares closed up 23 percent at C$.08 per share in Thursday trade on the TSX Venture Exchange.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.